QYUNS-B (02509): QX001S (Selsun , ustekinumab injection) has been approved for supplemental application for plaque psoriasis in children.

QYUNS-B (02509) announced that on March 3, 2025, Zhongmei Huadong received the National Medical Products Administration (NMPA) approved and issued "Drug Supplementary Application Approval Notice". The supplementary application for QX001S to add the indication of pediatric plaque psoriasis has been approved. QX001S is a biosimilar of the original product Stelara (ustekinumab injection), which works by blocking the binding of the p40 subunit shared by IL-12 and IL-23 to the IL-12R1 receptor protein on target cells, thereby inhibiting IL-12 and IL-23 mediated signaling and cytokine cascades. IL-12 and IL-23 are two naturally occurring cytokines that play a key role in immune-mediated inflammatory diseases.